Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER)
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
• Patient gives voluntary written informed consent to participate in the study and are capable of reading and understanding questionnaires or forms in English or Spanish.
• Patients with a diagnosis of ILD based on computed tomography imaging, including:
‣ Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis
⁃ Connective tissue disease-associated ILD with forced vital capacity (FVC) \<70%
⁃ Hypersensitivity pneumonitis
⁃ Scleroderma-related ILD
⁃ Autoimmune ILD
⁃ Nonspecific interstitial pneumonia
⁃ Occupational lung disease
⁃ Combined pulmonary fibrosis and emphysema with mild emphysema on lung imaging as determined by the Investigator
• Patients must have at least 2 signs or symptoms suggestive of PH, as specified by the study protocol.